Skip to main content
SpringerLink
Log in
Book cover

The 21st Century Handbook of Clinical Ovarian Cancer pp 83–114Cite as

Emerging therapies

  • Chapter
  • First Online:

  • 992 Accesses

Abstract

Novel agents that target specific signal transduction pathways discussed in the previous chapter have entered the clinical arena in both drug development and phase III clinical trials in ovarian cancer. In this chapter we will review several of the emerging therapies that have been combined with traditional chemotherapy for advanced and recurrent ovarian cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.

    Google Scholar 

  2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.

    Google Scholar 

  3. Oza AM, Perren TJ, Swart AM, et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer. 2013;49(Suppl3):LBA6.

    Google Scholar 

  4. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-2045.

    Google Scholar 

  5. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.

    Google Scholar 

  6. Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Sep 15. [Epub ahead of print].

    Google Scholar 

  7. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer. 2013;49:(suppl 3):abstr LBA10.

    Google Scholar 

  8. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30:362-371.

    Google Scholar 

  9. Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799-808.

    Google Scholar 

  10. Amgen. News Release Details. Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer. www.amgen. com/media/media_pr_detail.jsp?year = 2014&releaseID = 1985448. Published November 4, 2014. Last accessed November 17, 2014.

  11. Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer. 2013;23(suppl 1):abstr LBA1.

    Google Scholar 

  12. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels. Cancer. 2010;116:1859‑1871.

    Google Scholar 

  13. ThermaSolutions. Enhanced outcome with intraperitoneal hyperthermia. The ThermoChemTM HT System. www.thermasolutions.com/images/HT-1000_Brochure.pdf. Last accessed November 17, 2014.

  14. Fagotti A, Constantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity‑related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221-225.

    Google Scholar 

  15. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.

    Google Scholar 

  16. Endocyte. The future of precision medicine. www.endocyte.com. Last accessed November 17, 2014.

  17. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400-4406.

    Google Scholar 

  18. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134. Em e r g i n g T h e r a p i e s • 113

    Google Scholar 

  19. O’Shaughnessy J, Osborne C, Pippen M, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol. 2009;27:18 s (suppl; abstr 3)

    Google Scholar 

  20. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof‑of‑concept trial. Lancet. 2010;376:245-251.

    Google Scholar 

  21. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852-861.

    Google Scholar 

  22. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372-379.

    Google Scholar 

  23. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.

    Google Scholar 

  24. Oza AM, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label phase II study. J Clin Oncol. 2012;30:(suppl):abstr 5001.

    Google Scholar 

  25. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymersase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882-892.

    Google Scholar 

  26. Ihnen M, zu Eluenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12:1002-1015.

    Google Scholar 

  27. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous cacinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14:134-140.

    Google Scholar 

  28. Shih I-M, Wang T-L. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67:1879-1882.

    Google Scholar 

  29. Yang G, Chang B, Yang F, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Coin Cancer Res. 2010;16:3171-3181.

    Google Scholar 

  30. Matulonis UA, Sharma S, Ghamande S, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or –refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012;127:63-69.

    Google Scholar 

  31. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA‑9090) in patients with solid malignancies. BMC Cancer. 2013;13:152-161.

    Google Scholar 

  32. Liu J, Barry WT, Birrer MJ, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15:1207-1214.

    Google Scholar 

  33. Monk BJ, Sill MW, Walker J, et al; Gynecologic Oncology Group. Bevacizumab with or without fosbretabulin tromethamine in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Presented at: 15th Biennial Meeting of the International Gynecologic Cancer Society; November 8–11, 2014; Melbourne, Australia. Abstract OS02.

    Google Scholar 

  34. Brueseke TJ, Tewari KS. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol. 2013;5:13-19.

    Google Scholar 

  35. Bristol Myers Squibb. Mechanism of action. https://www.hcp.yervoy.com/pages/mechanismof-action.aspx. Last accessed November 17, 2014. 114 • The 21st Century Handbook of Clinical Ovarian Cancer

  36. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. Slides presented at: 2012 ASCO Annual Meeting; June 1–June 5, 2013; Chicago, IL. Abstract CRA2509.

    Google Scholar 

  37. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.

    Google Scholar 

  38. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.

    Google Scholar 

  39. Cannon MJ, Goyne H, Stone PJ, Chiriva-internati M. Dendritic cell vaccination against ovarian cancer – tipping the Treg/TH17 balance to therapeutic advantage. Expert Opin Biol Ther. 2011;11:441-445.

    Google Scholar 

  40. Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer as a predictor of outcome following bevacizumab. J Clin Oncol. 2014;32:5 s (suppl; abstr 5502).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, Irvine Medical Gynecologic Oncology Group, Orange, CA, USA

    Krishnansu Tewari

  2. St Joseph’s Hospital and Medical Center Division of Gynecologic Oncology, Phoenix, AZ, USA

    Bradley Monk

Authors
  1. Krishnansu Tewari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradley Monk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tewari, K., Monk, B. (2015). Emerging therapies. In: The 21st Century Handbook of Clinical Ovarian Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-08066-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08066-6_6

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08065-9

  • Online ISBN: 978-3-319-08066-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation